Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Poster Session C

Spondyloarthritis (SpA) including psoriatic arthritis (PsA)

Session: (2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III: SpA

2254: The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Tuesday, November 14, 2023
9:00 AM – 11:00 AM PT
Location: Poster Hall
On Demand In Person

    Abstract Poster Presenter(s)

  • Ruoning (Lemon) Ni, MD (she/her/hers)

    University of Iowa Hospitals and Clinics
    Coralville, IA, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

Ruoning Ni1, Jiayi Zheng2, Ruru Guo3 and Bharat Kumar4, 1University of Iowa Hospitals and Clinics, Coralville, IA, 2The Wright Center for Graduate Medical Education, Scranton, PA, 3Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 4University of Iowa Hospitals and Clinics, Iowa City, IA

Background/Purpose: The aim of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with psoriasis (PsO) or psoriatic arthritis (PsA).

Methods: A search for randomized controlled trials of patients with PsO/PsA treated with IL-17 inhibitors that reported confirmed MACEs was conducted on December 7, 2022, in Medline, Embase, and the Cochrane Library for Randomized Controlled Trials. Two reviewers screened titles and abstracts and selected papers for full-text review. Trials that included the previous use of biologic disease modifying anti-rheumatic drugs were excluded. Risk ratios were calculated by the Mantel-Haenszel random-effect method. Heterogeneity across studies was measured by χ2 test and I2 statistics. Funnel plot analysis was produced to detect potential publication bias.

Results: Of the 919 references identified, 9 RCT studies were eligible for quantitative synthesis (n=2096 patients). The use of IL-17 inhibitors was not correlated with a statistically significant change in the risk of MACEs (Risk Ratio 0.56; 95% CI 0.15 to 2.14; p= 0.40). Subgroup analysis of secukinumab or ixekizumab also did not demonstrate changes in the risk for MACEs. Additionally, there was no detectable dose-dependent effect of IL-17 inhibitors on the risk of MACEs.

Conclusion: IL-17 inhibitor use is not correlated with a change in risk for major adverse cardiovascular in patients with PsO/PsA that have not previously received biologic disease-modifying anti-rheumatic drugs.


Flow chart of included randomized controlled trials.


Relative Risks (RRs) of all major adverse cardiovascular events (MACEs) in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA) treated with interleukin 17 (IL-17) inhibitors compared with placebo or disease-modifying antirheumatic drugs (DMARDs) in randomized controlled trials (RCTs) using the Mantel-Haenszel (M-H) random-effect method. P-Y, patient-year.


RRs of all MACEs in patients with PsO/PsA treated with different dosages of IL-17 inhibitors in RCTs using the M-H random-effect method. P-Y, patient-year.


R. Ni: None; J. Zheng: None; R. Guo: None; B. Kumar: None.